...in oncology innovation with more than 75 clinical study...
In Cohort 1 of the BLC3001 (NCT03390504, THOR) study: Serious adverse reactions occurred in 41% of patients who received BALVERSA®. Serious reactions in >2% of patients included urinary tract infection (4.4%), hematuria (3.7%),...